Tao Yin

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice

Ling Li, Linjiang Song, Xiaowei Liu et al. · ACS Nano · 2016 · 236 citations

Engineering, Molecular Biology, Gene Delivery +16

Up‐regulation of glycolysis promotes the stemness and <scp>EMT</scp> phenotypes in gemcitabine‐resistant pancreatic cancer cells

Hengqiang Zhao, Qingke Duan, Zhengle Zhang et al. · Journal of Cellular and Molecular Medicine · 2017 · 160 citations · Full text

Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade

Zhengle Zhang, Qingke Duan, Hengqiang Zhao et al. · Cancer Letters · 2016 · 150 citations

Tumor Biology, Oncology, Pancreatic Cancer Stemness +8